title: Earlobe sarcoidosis.
abstract: BACKGROUND
  Infliximab, a TNF-alpha blocking agent, is an upcoming therapeutic option for cases of refractory sarcoidosis. In pulmonary sarcoidosis, changes imaged by 18F-FDG-PET during infliximab treatment in sarcoidosis patients correlate with signs of clinical improvement.
  
  
  METHODS
  Case-report.
  
  
  CONCLUSIONS
  A patient with severe earlobe sarcoidosis, treated with infliximab, is presented. This case shows that even relatively small extrapulmonary localisations of sarcoidosis can be visualised by 18F-FDG-PET, and that a decrease of FDG-uptake correlates well with clinical improvement on infliximab treatment.
authors: Centre of Interstitial Lung Diseases, Department of pulmnonology, St Antonius Hospital, Nieuwegein, The Netherlands. a.vorselaars@antoniusziekenhuis.nl
authors: A D M
authors: AD
authors: Vorselaars
authors: R G M
authors: RG
authors: Keijsers
authors: J C
authors: JC
authors: Grutters
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D054644:Ear Auricle / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology; D004427:Ear Diseases / Q000175:diagnosis / Q000188:drug therapy; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D012507:Sarcoidosis / Q000175:diagnosis / Q000188:drug therapy; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D000069285:Infliximab